Introduction to Section I: The Relevance of CF Diagnostic Tools for Measuring Restoration of CFTR Function After Therapeutic Interventions in Human Clinical Trials

Methods in Molecular Biology

Volumn 741, Issue , 2011, Pages 3-11

  De Boeck, Kris ^a   Ashlock, Melissa ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Cystic Fibrosis Foundation Therapeutics   (United States)

Author keywords

Cystic fibrosis; diagnostic tests; new therapies; outcome parameters

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; EDITORIAL; HUMAN; METABOLISM; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; TREATMENT OUTCOME;

EID: 80052307732     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-117-8_1     Document Type: Chapter

References (37)

1. WHO (2004) The molecular genetic epidemiology of cystic fibrosis. Report of a joint meeting of WHO/ ECFTN/ICF(M)A/ECFS http://www. who.int/genomics/publications/en/and WHO Geneva, Human Genetics Programme WHO/HGN/CF/WG/04.02.
2. Buzzetti, R., Salvatore, D., Baldo, E., Forneris, M. P., Lucidi, V., Manunza, D., et al. (2009) An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. J. Cyst. Fibros. 8, 229–237.
3. CFF (2007) CFF patient Registry annual data report 2007. Available from: http:// www.cff.org/UploadedFiles/research/ ClinicalResearch/2007-Patient-Registry-Report.pdf
4. Dodge, J. A., Lewis, P.A., Stanton, M., and Wilsher, J., (2007) Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur. Respir. J. 29, 522–526.
5. ECFS. (2009) European Registry for Cystic Fibrosis, Report 2006. http://www.ecfs.eu/files/webfm/webfiles/File/ecfs_registry/ECFRreport2006.pdf
6. Lebecque, P., Leal, T., De Boeck, C., Jaspers, M., Cuppens, H., and Cassiman, J. J. (2002) Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am. J. Resp. Crit. Care Med. 165, 757–761.
7. De Boeck, K., Wilschanski, M., Castellani, C., Taylor, C., Cuppens, H., Dodge, J., et al. (2006) Cystic fibrosis: Terminology and diagnostic algorithms. Thorax 61, 627–635.
8. Rosenstein, B. J., and Cutting, G. R. (1998) The diagnosis of cystic fibrosis: A consensus statement. Cystic fibrosis foundation consensus panel. J. Pediatr. 132, 589–595.
9. Henry, R. L., Mellis, C. M., and Petrovic, L. (1992) Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol. 12, 158–161.
10. Ashlock, M. A., Beall, R. J., Hamblett, N. M., Konstan, M. W., Penland, C. M., Ramsey, B. W., et al. (2009) A pipeline of therapies for cystic fibrosis. Semin. Respir. Crit. Care Med. 30, 611–626.
11. Frederiksen, B., Koch, C., and Hoiby, N. (1997) Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23, 330–335.
12. Proesmans, M., Balinska-Miskiewicz, W., Dupont, L., Bossuyt, X., Verhaegen, J., Høiby, N., et al. (2006) Evaluating the “Leeds criteria” for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur. Respir. J. 27, 937–943.
13. Borowitz, D., Durie, P. R., Clarke, L. L., Werlin, S. L, Taylor, C. J., Semler, J., et al. (2005) Gastrointestinal outcomes and con-founders in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 41, 273–285.
14. Colombo, C. (2007) Liver disease in cystic fibrosis. Curr. Opin. Pulm. Med. 13, 529–536.
15. Quinton, P. M. (2007) Cystic fibrosis: Lessons from the sweat gland. Physiology (Bethesda) 22, 212–225.
16. Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., et al. (2008) Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic fibrosis foundation consensus report. J. Pediatr. 153, S4–S14.
17. Bush, A. (2008) Editorial overview: Newborn screening for cystic fibrosis – Benefit or bane? Paediatr. Resp. Rev. 9, 301–302.
18. LeGrys, V. A., Yankaskas, J. R., Quittell, L. M., Marshall, B. C., and Mogayzel, P. J. Jr. (2007) Diagnostic sweat testing: The Cystic Fibrosis Foundation guidelines. J. Pediatr. 151, 85–89.
19. Collins, F. S. (1992) Cystic fibrosis: Molecular biology and therapeutic implications. Science 256, 774–779.
20. Goubau, C., Wilschanski, M., Skalicka, V., Lebecque, P., Southern, K. W., Sermet, I., et al. (2009) Phenotypic characterisation of patients with intermediate sweat chloride values: Towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax 64, 683–691.
21. Knowles, M. R., Paradiso, A. M., and Boucher, R. C. (1995) In vivo nasal potential difference: Techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum. Gene Ther. 6, 445–455.
22. Middleton, P. G., Geddes, D. M., and Alton, E.W. (1994) Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur. Respir. J. 7, 2050–2056.
23. De Boeck, C., Derichs, N., Fajac, I., et al. (2011) New clinical diagnostic procedures for cystic fibrosis in Europe. J. Cyst. Fibros. 10 Suppl 1, S53–S66.
24. Rowe, S. M., Accurso, F., and Clancy, J. P. (2007) Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc. Am. Thorac. Soc. 4, 387–398.
25. Highsmith, W. E., Burch, L. H., Zhou, Z., et al. (1994) A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N. Engl. J. Med. 331, 974–980.
26. Wilschanski, M., Dupuis, A., Ellis, L., Jarvi, K., Zielenski, J., Tullis E., et al. (2006) Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am. J. Respir. Crit. Care Med. 174, 787–794.
27. Corey, M., Edwards, L., Levison, H., and Knowles, M. (1997) Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J. Pediatr. 131, 809–814.
28. Morgan, R. M., Patterson, M. J., and Nimmo, M.A. (2004) Acute effects of dehydration on sweat composition in men during prolonged exercise in the heat. Acta Physiol. Scand. 182, 37–43.
29. Yilmaz, K., Tatli, B., Yaramis, A., Aydinli, N., Caliskan, M., and Ozmen, M. (2005) Symptomatic and asymptomatic hypohidro-sis in children under topiramate treatment. Turk. J. Pediatr. 47, 359–363.
30. Wilschanski, M., Famini, H., Strauss-Liviatan, N., Rivlin, J., Blau, H., Bibi, H., et al. (2001) Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur. Respir. J. 17, 1208–1215.
31. Griesenbach, U., and Boyd, A. C. (2005) Pre-clinical and clinical endpoint assays for cystic fibrosis gene therapy. J. Cyst. Fibros. 4, 89–100.
32. Rosenfeld, M. (2007) An overview of end-points for cystic fibrosis clinical trials: One size does not fit all. Proc. Am. Thorac. Soc. 4, 299–301.
33. Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M., et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial. Lancet 372, 719–727.
34. Sermet-Gaudelus, I., Boeck, K. D., Casimir, G. J., et al. (2010) Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med. 182, 1262–1272.
35. Accurso, F. J., Rowe, S. M., Clancy, J. P., et al. (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363, 1991–2003.
36. Ashlock, M., and Olson, E. R. (2011) Therapeutics development for cystic fibrosis: a successful model for a multisystemic genetic disease. Annu. Rev. Med. 62, 107–125.
37. De Boeck, C., Bulteel, V., Tiddens, H., et al. (2011) Guideline on the design and conduct of CF clinical trials: the ECFS Clinical Trials Network (ECFS-CTN). J. Cyst. Fibros. 10 Suppl 1, S67–S74.